Reports Q2 revenue $38.59B, consensus $37.9B. CEO Tim Wentworth said: “Second quarter results reflect disciplined cost management and improvement in U.S. Healthcare, which were partially offset by weaker front-end results in U.S. Retail Pharmacy, while significant legal settlements resulted in continued negative free cash flow. We remain in the early stages of our turnaround plan, and continue to expect that meaningful value creation will take time, enhanced focus and balancing future cash needs with necessary investments to navigate a changing pharmacy and retail landscape.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WBA:
- WBA Lawsuit Alert! Class Action Lawsuit Against Walgreens Boots Alliance
- BofA says Hims & Hers Zepbound sales will be ‘immaterial’
- Walgreens to pay over $2.8M to settle False Claims Act allegations
- Walgreens Boots Alliance Inc. (WBA) Q2 Earnings Cheat Sheet
- Walgreens’ executive chair Pessina to double stake after takeover, FT reports